Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
Mood Disorders Psychopharmacology Unit, University Health Network, Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Ann Clin Psychiatry. 2022 Nov;34(4):264-274. doi: 10.12788/acp.0082.
Postpartum depression (PPD) is a severe, debilitating mood disorder with consequences for both mothers and children, highlighting the need for rapid-acting and effective treatments for PPD. The aim of this narrative review is to synthesize the available literature on the administration of ketamine for PPD and propose ketamine as a viable and advantageous treatment.
A search was conducted on MEDLINE/PubMed, PsycInfo, and Embase databases from inception to October 10, 2021 for preclinical studies, interventional studies (ie, open-label and randomized controlled trials), as well as systematic reviews and meta-analyses evaluating the use of ketamine in postpartum populations. Completed and ongoing clinical trials were identified on ClinicalTrials.gov.
Four clinical trials were identified. Results from this review support additional investigation into ketamine as a potential treatment for PPD.
Ketamine may be a favorable option for treating PPD due to its antidepressive and analgesic effects, short infusion time, and rapid clearance from the maternal bloodstream. However, there is insufficient evidence to support its use in this population, underscoring the importance of additional clinical research investigating ketamine for PPD.
产后抑郁症(PPD)是一种严重的、使人虚弱的情绪障碍,对母亲和孩子都有影响,这凸显了对 PPD 的快速起效和有效治疗的需求。本综述的目的是综合现有关于氯胺酮治疗 PPD 的文献,并提出氯胺酮作为一种可行且有利的治疗方法。
从 MEDLINE/PubMed、PsycInfo 和 Embase 数据库的建立到 2021 年 10 月 10 日,对评估氯胺酮在产后人群中应用的临床前研究、干预性研究(即开放标签和随机对照试验)以及系统评价和荟萃分析进行了检索。在 ClinicalTrials.gov 上确定了已完成和正在进行的临床试验。
确定了四项临床试验。本综述的结果支持进一步研究氯胺酮作为 PPD 的潜在治疗方法。
由于氯胺酮具有抗抑郁和镇痛作用、输注时间短以及从母体血液中快速清除,因此它可能是治疗 PPD 的一个有利选择。然而,目前的证据还不足以支持在该人群中使用氯胺酮,这突显了进行更多针对氯胺酮治疗 PPD 的临床研究的重要性。